CAL
ELVN icon

Capital Advisors Ltd’s Enliven Therapeutics ELVN Stock Holding History

Capital Advisors Ltd’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-302
Closed -$7K – 1400
2024
Q4 		$7K Hold
302
– – ﹤0.01% 860
2024
Q3 		$8K Hold
302
– – ﹤0.01% 818
2024
Q2 		$7K Buy
+302
New +$6.36K ﹤0.01% 825

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Capital Advisors Ltd's ELVN Position: Q1 2025 in Review

Capital Advisors Ltd sold out of Enliven Therapeutics (ELVN) in Q1 2025, closing a stake of 302 shares — an estimated $7K sold.

Capital Advisors Ltd first reported a position in ELVN in Q2 2024 and held it in 3 quarters. The position peaked at $8K in Q3 2024. 121 funds tracked by Wall St. Rank hold ELVN as of Q1 2025.

  • Capital Advisors Ltd reported no remaining Enliven Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Capital Advisors Ltd sold 302 Enliven Therapeutics shares in Q1 2025, an estimated $7K.
  • Capital Advisors Ltd first reported a position in Enliven Therapeutics in Q2 2024 and held it in 3 quarters.
  • Capital Advisors Ltd's Enliven Therapeutics position peaked at $8K in Q3 2024.
  • 121 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2025.

Based on Capital Advisors Ltd's 13F filing for Q1 2025, filed 15 Apr 2025.